A prospective cross-over study comparing the effect of mycophenolate versus azathioprine on allograft function and viral load in liver transplant recipients with recurrent chronic HCV infection

Liver Transplantation

Volumn 10, Issue 1, 2004, Pages 52-57

  Zekry, Amany ^a   Gleeson, Margret ^a   Guney, Seren ^a   McCaughan, Geoffrey W ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ALANINE AMINOTRANSFERASE; AZATHIOPRINE; CYCLOSPORIN; GANCICLOVIR; MESSENGER RNA; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; TACROLIMUS; VIRUS RNA;

ACUTE GRAFT REJECTION; ADULT; ANTIVIRAL ACTIVITY; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG POTENTIATION; FEMALE; HEPATITIS C; HERPES ZOSTER; HUMAN; LIVER FUNCTION; LIVER GRAFT; LIVER TRANSPLANTATION; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECIPIENT; RECURRENT INFECTION; STATISTICAL ANALYSIS; VIRUS LOAD;

AZATHIOPRINE; CREATININE; CROSS-OVER STUDIES; CYCLOSPORINE; FEMALE; HEPATITIS C; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; PROSPECTIVE STUDIES; RECURRENCE; VIRAL LOAD;

EID: 3042771789     PISSN: 15276465     EISSN: None     Source Type: Journal    
DOI: 10.1002/lt.20000     Document Type: Article

References (19)

1. Berenguer M, Ferrell L, Watson J, Prieto M, Kim M, Rayon M, Cordoba J, et al. HCV-related fibrosis progression following liver transplantation: increase in recent years. J Hepatol 2000;32: 673-684.
2. Gane EJ, Naoumov NV, Qian KP, Mondelli MU, Maertens G, Portmann BC, Lau JY, et al. A longitudinal analysis of hepatitis C virus replication following liver transplantation. Gastroenterology 1996;110:167-177.
3. Ballardini G, De Raffele E, Groff P, Bioulac-Sage P, Grassi A, Ghetti S, Susca M, et al. Timing of reinfection and mechanisms of hepatocellular damage in transplanted hepatitis C virus-reinfected liver. Liver Transpl 2002;8:10-20.
4. Doughty AL, Spencer JD, Cossart YE, McCaughan GW. Cholestatic hepatitis after liver transplantation is associated with persistently high serum hepatitis C virus RNA levels. Liver Transpl Surg 1998;4:15-21.
5. Pelletier SJ, Raymond DP, Crabtree TD, Berg CL, Iezzoni JC, Hahn YS, Sawyer RG, et al. Hepatitis C-induced hepatic allograft injury is associated with a pretransplantation elevated viral replication rate. Hepatology 2000;32:418-426.
6. Neyts J, Andrei G, De Clercq E. The novel immunosuppressive agent mycophenolate mofetil markedly potentiates the antiherpesvirus activities of acyclovir, ganciclovir, and penciclovir in vitro and in vivo. Antimicrob Agents Chemother 1998;42:216-222.
7. Neyts J, De Clercq E. The anti-herpesvirus activity of (1'S,2'R)-9-[[1′,2′-bis(hydroxymethyl)-cycloprop-1′ -yl]methyl]guanine is markedly potentiated by the immunosuppressive agent mycophenolate mofetil. Antiviral Res 2001;49:121-127.
8. Gong ZJ, De Meyer S, Clarysse C, Verslype C, Neyts J, De Clercq E, Yap SH. Mycophenolic acid, an immunosuppressive agent, inhibits HBV replication in vitro. J Viral Hepat 1999;6: 229-236.
9. Platz KP, Mueller AR, Willimski C, Mansoorian B, Berg T, Neuhaus R, Hopf U, et al. Indication for mycophenolate mofetil therapy in hepatitis C patients undergoing liver transplantation. Transplant Proc 1998;30:2232-2233.
10. Wiesner R, Rabkin J, Klintmalm G, McDiarmid S, Langnas A, Punch J, McMaster P, et al. A randomized double-blind comparative study of mycophenolate mofetil and azathioprine in combination with cyclosporine and corticosteroids in primary liver transplant recipients. Liver Transpl 2001;7: 442-450.
11. Fasola CG, Netto G, Christensen LL, Rakela J, Thomas M. Lower incidence of early HCV-RNA levels and HCV recurrence post liver transplantation in patients induced with Mycophenolate Myfetil: a high-dose benefit. Am J Transplant 2002;2:196.
12. Jain A, Kashyap R, Demetris AJ, Eghstesad B, Pokharna R, Fung JJ. A prospective randomized trial of mycophenolate mofetil in liver transplant recipients with hepatitis C. Liver Transpl 2002;8:40-46.
13. Nelson DR, Soldevila-Pico C, Reed A, Abdelmalek MF, Hemming AW, Van der Werf WJ, Howard R, et al. Anti-interleukin-2 receptor therapy in combination with mycophenolate mofetil is associated with more severe hepatitis C recurrence after liver transplantation. Liver Transpl 2001;7:1064-1070.
14. Brouwer JT, Hansen BE, Niesters HG, Schalm SW. Early prediction of response in interferon monotherapy and in interferon-ribavirin combination therapy for chronic hepatitis C: HCV RNA at 4 weeks versus ALT. J Hepatol 1999;30:192-198.
15. Scheuer PJ. The nomenclature of chronic hepatitis: time for a change. J Hepatol 1995;22:112-114.
16. Charlton MR. Mycophenolate and hepatitis C: salve on a wound or gasoline on a fire? Liver Transpl 2002;8:47-49.
17. Firpi RJ, Nelson DR, Davis GL. Lack of antiviral effect of a short course of mycophenolate mofetil in patients with chronic hepatitis C virus infection. Liver Transpl 2003;9:57-61.
18. Rostaing L, Izopet J, Sandres K, Cisterne JM, Puel J, Durand D. Changes in hepatitis C virus RNA viremia concentrations in long-term renal transplant patients after introduction of mycophenolate mofetil. Transplantation 2000;69:991-994.
19. Ong JP, Barnes DS, Younossi ZM, Gramlich T, Yen-Lieberman B, Goormastic M, Sheffield C, et al. Outcome of de novo hepatitis C virus infection in heart transplant recipients. Hepatology 1999;30:1293-1298.